Company / Working Capital
Cullinan Therapeutics, Inc. Working Capital History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$384.0M
FY2024
5-year range
$198.0M / $452.1M
FY2020-FY2024
Trend
-15.0%
vs FY2023
Sector context
#114 of 213
Health Care
What the data says
At $384M, Cullinan Therapeutics, Inc.'s working capital ranks #114 of 213 in the Health Care sector. Declined from $452M to $384M over the past 2 years.
Based on SEC 10-K filings.
$384M in FY2024 with a 3-year CAGR of +10.5%.
Declined from $452M to $384M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +10.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#114 of 213 in Health CareTop 54% of 213This company $384.0M Sector average $934.6M
▼
-58.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +10.5%, indicating consistent growth.
- In FY2024, working capital decreased 15.0% year-over-year.
- Ranks #114 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $384.0M | -15.0% |
| FY2023 | $452.1M | +0.0% |
| FY2022 | $452.0M | +58.7% |
| FY2021 | $284.8M | +43.9% |
| FY2020 | $198.0M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026